GOLDEN PARTNERS
Canon Medical offers a wide range of diagnostic and interventional medical equipment (CT, MR, UL and RX), as well as a comprehensive set of image post-processing IT solutions. Under the motto "Made for Life", Canon Medical contributes favorably to hospital management and offers all kinds of healthcare systems and services adapted to the patient, maintaining its long tradition of contributing to healthcare.
We work hand in hand with our collaborators: the medical, academic and research community. We start our relationships based on transparency, sincerity and respect. Working together, we seek to create leading solutions that help enrich the quality of life.
With a presence in more than 150 countries, more than 100 years of experience, 5 factories and 11 dedicated Research and Development Centers, Canon Medical ranks first among Japanese companies, and third in the US, in R&D leadership.
We are a pharmaceutical company driven by technological leadership in research and development, commercial excellence, access to treatments and data science. Novartis reimagines medicine to improve and extend people's lives. Our innovative treatments and therapies, which have helped improve the lives of more than 750 million people around the world and 10 million in Spain in 2021, cover most pathologies, from cardiovascular disease and cancer to rare diseases of origin genetic. That is our purpose. We have evolved as an organization over centuries, since 1750, to always remain at the forefront of knowledge and thus achieve a positive impact on the health of the population.
At Palex Medical we are working to become a global supplier to the healthcare sector.
We base our development and growth on the constant search for innovation, improvement and the desire to respond and provide global solutions to our customers.
Our goal is to be at the side of patients and healthcare professionals, reaching the level of experts to be able to drive significant changes in our sector.
Palex Commercial contact: palex@palexmedical.com or Tel. 934 006 500
Our mission is to offer health transport services with the highest quality standards, combining the best human and material resources. We have state-of-the-art equipment and we employ more than 1,200 professionals from the health sector, these being our main differentiating element, as well as their management model, based on dynamism, communication between sector agents and oriented to the end user , to offer the best solutions to each transfer and with the confidence of a well-done service.
We are people and we work for people. We carry out more than 600,000 services (covering more than 500,000 users) annually.
Social responsibility is a fact in our country, contributing to the economic and social improvement of our immediate surroundings (collaborating with medical research), as well as respect for the environment (participating in reforestation projects), and helping the Third world communities (donating ambulances and medical supplies in Africa).
Werfen is a growing private company, founded in 1966 in Barcelona, Spain.
We are world leaders in specialized diagnostics, in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity. Through our commercial line of OEM, manufacturer of Original Equipment for third parties, we research, develop and produce customized tests and biomaterials.
Currently, we operate directly in more than 30 countries and are present in more than 100 territories through distributors. Our R&D and production centers are located in the United States and Europe. In 2020, our revenues reached 1,696 million euros and we have a team of 5,501 employees.
ROVI is a pan-European pharmaceutical company, specialized and dedicated to the research, development, manufacturing under license and commercialization of small molecules and biological specialties.
The company, in a continuous process of international expansion, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than 40 marketed products, in which its reference product, Bemiparin, stands out. which is already marketed in 58 countries around the world.
Likewise, in 2017, ROVI began marketing its enoxaparin biosimilar, developed internally, in Europe. ROVI continues to develop the ISM® Platform technology, a cutting-edge line of research in the field of prolonged drug release with proven advantages. Listed on the Stock Exchange since 2007, in December 2021 it was included in the IBEX 35.
SILVER PARTNERS
BRONZE PARTNERS
